IDEAYA Biosciences (IDYA)
39.86
-0.11 (0.28%)
Upcoming Events
Latest Headlines
Ideaya Biosciences (IDYA) Reiterated at Market Outperform by Citizens on IDE849 Advances
September 1, 2026 4:23 AM - StreetInsider
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 28, 2026 6:00 AM - PR NewsWire
IDEAYA and Genentech to test drug combo in pancreatic cancer
August 19, 2026 6:01 AM - StreetInsider
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
August 19, 2026 6:00 AM - PR NewsWire
Form SCHEDULE 13G IDEAYA Biosciences, Inc. Filed by: BAKER BROS. ADVISORS LP
August 14, 2026 4:03 PM - SEC Filing
Form 10-Q IDEAYA Biosciences, Inc. For: Jun 30
August 4, 2026 4:07 PM - SEC Filing
IDEAYA Biosciences (IDYA) Misses Q2 EPS by 16c
August 4, 2026 6:19 AM - StreetInsider
Form 8-K IDEAYA Biosciences, Inc. For: Aug 04
August 4, 2026 6:05 AM - SEC Filing
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
August 4, 2026 6:00 AM - PR NewsWire
Form SCHEDULE 13G IDEAYA Biosciences, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC
July 31, 2026 10:18 AM - SEC Filing
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 31, 2026 6:00 AM - PR NewsWire
IDEAYA Biosciences starts Phase 1/2 expansion for IDE892 in cancer
July 27, 2026 6:00 AM - StreetInsider
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancer
July 27, 2026 6:00 AM - PR NewsWire
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
July 17, 2026 9:00 AM - PR NewsWire
Form 4 IDEAYA Biosciences, Inc. For: Jul 07 Filed by: Ruiz Briseno Andres
July 9, 2026 4:57 PM - SEC Filing
Form 144 IDEAYA Biosciences, Inc. Filed by: Ruiz Briseno Andres
July 7, 2026 4:55 PM - SEC Filing
Ideaya Biosciences (IDYA) PT Lowered to $48 at RBC Capital
July 7, 2026 8:00 AM - StreetInsider
Ideaya Biosciences (IDYA) PT Lowered to $63 at Truist Securities
July 7, 2026 7:09 AM - StreetInsider
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 26, 2026 6:00 AM - PR NewsWire
Form 8-K IDEAYA Biosciences, Inc. For: Jun 16
June 23, 2026 4:06 PM - SEC Filing
Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: YARNO WENDY L
June 18, 2026 4:34 PM - SEC Filing
Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: Stein Jeffrey
June 18, 2026 4:34 PM - SEC Filing
Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: ROSEN TERRY J
June 18, 2026 4:33 PM - SEC Filing
Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: Morrison Scott W
June 18, 2026 4:33 PM - SEC Filing
Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: MACKEY CATHERINE J
June 18, 2026 4:32 PM - SEC Filing
Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: Hampton Malcolm Garret
June 18, 2026 4:31 PM - SEC Filing
IDEAYA Biosciences names CEO Yujiro Hata as board chairman
June 17, 2026 6:01 AM - StreetInsider
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
June 17, 2026 6:00 AM - PR NewsWire
IDEAYA starts phase 1/2 trial of IDE892 for pancreatic, lung cancers
June 15, 2026 6:00 AM - StreetInsider
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
June 15, 2026 6:00 AM - PR NewsWire
Form 8-K IDEAYA Biosciences, Inc. For: Jun 08
June 10, 2026 4:10 PM - SEC Filing
IDEAYA Biosciences closes $345 million public offering
June 10, 2026 4:05 PM - StreetInsider
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
June 10, 2026 4:05 PM - PR NewsWire
Form 424B5 IDEAYA Biosciences, Inc.
June 9, 2026 5:17 PM - SEC Filing
Ideaya Biosciences (IDYA) Reiterated at Market Outperform by Citizens
June 9, 2026 4:57 AM - StreetInsider
Full Article List